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BACKGROUND: Treatments for symptom control in osteoarthritis (OA) confer 
varying degrees of beneﬁ ts alongside medication-related risks. Physicians’ preferences 
over beneﬁ ts and risks of NSAIDS are an important aspect of understanding clinical 
practice. OBJECTIVES: To estimate physicians’ preferences over beneﬁ ts and risks 
associated with NSAID use in the management of OA and examine differences in 
preferences between general practitioners (GPs) and specialists. METHODS: Partici-
pating physicians treated at least 10 OA patients per-month. Each physician was 
randomized to receive one of four blocks of discrete-choice questions; each block 
consisting of 12 paired choice tasks comparing treatment proﬁ les. Treatment proﬁ les 
were deﬁ ned by four beneﬁ ts (ambulatory pain, resting pain, stiffness, difﬁ culty doing 
daily activities) and four medication-related risks (bleeding ulcer, stroke, heart attack, 
hypertension), each varying across four clinically meaningful levels. Elicitation of 
preferences was facilitated using standardized patient proﬁ les systematically varying 
by age, co-morbid conditions and clinically relevant risks of NSAIDs. Preference 
weights were estimated using mixed-effects logistic regression and were standardized 
on a 0–10 (low-high) importance scale. RESULTS: 477 physicians participated (61% 
GPs, 39% specialists). Reductions in ambulatory pain and difﬁ culty doing daily activi-
ties were the most important efﬁ cacy variables (6.45; 95%CI:4.8–8.2) followed by 
eliminating resting pain (3.18; 95%CI:1.9–4.5) and stiffness (2.79; 95%CI:1.5–4.1). 
Ambulatory pain was twice as important as resting pain or stiffness (P < 0.05). Risk 
of heart attack was the most important medication-related risk outcome (10.00; 
95%CI:7.6–12.4) followed by stroke (9.42; 95%CI:7.2–11.6), ulcer risk (4.62; 
95%CI:3.5–5.7) and hypertension (3.25; 95%CI:3.2–3.4). There were no statistically 
signiﬁ cant differences in preferences between GPs and specialists. CONCLUSIONS: 
Ambulatory pain and the incremental risk of heart attack were the most important 
NSAID-related attributes that inﬂ uence physicians’ treatment choices. Preferences did 
not vary between GPs and specialists. The ﬁ ndings conﬁ rm that beneﬁ t-risk tradeoffs 
are important aspects in treament selection for OA management.
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OBJECTIVES: Describe the potential economy of NSAIDs in a population of patients 
with osteoarthritis newly-treated with a sodium chondroitin sulphate (SCS) versus a 
control group. METHODS: The Disease Analyzer database (IMS), which collects 
medical data from 1240 representative French GPs was used. The control group 
consists of patient diagnosed with knee or hip osteoarthritis during the observation 
period but not treated with symptomatic slow acting drugs for osteoarthritis through-
out the study period, no during the year before the study or the following year. 
RESULTS: In total, 944 patients were included, 472 per group. The characteristics of 
both groups in terms of age, sex, time since diagnosis and type of osteoarthritis are 
strictly the same. 80% of patients included suffer from osteoarthritis of the knee. a 
total of 53.4% of patients included in study received one or more prescriptions for 
NSAIDs during the year prior to their inclusion. Half of the patients in the SCS group 
received at least one NSAID prescription during initiation or during the 1 year follow-
up period. This % is signiﬁ cantly higher in the control group (64%; P < 0.01). 18% 
of patients in the SCS group stopped their treatment with NSAIDs at the initiation of 
SCS and did not resume it during the follow-up year, versus 11% in the control group. 
This difference is signiﬁ cant (p = 0.01). Patients in the SCS group require signiﬁ cantly 
fewer days of treatment with NSAIDs expressed in DDD than patients in the control 
group: on average 49 days of treatment versus 64 (p = 0.01). CONCLUSIONS: One 
of the public health goals set by health authorities—to reduce the incidence of iatro-
genic complications (serious bleeding or gastroduodenal events) by 20% in osteoar-
thritic patients could be attained by a prescription of SCS. Indeed, this study highlights 
the fact that, in actual use, patients in the SCS group are signiﬁ cantly less likely to use 
NSAIDs (−22%).
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OBJECTIVES: To describe the use NSAIDs in a population of patients with osteoar-
thritis newly-treated (2009) by a symptomatic slow acting drugs for Osteoarthritis 
(SYSADOA) METHODS: The Disease Analyzer database (IMS), which collects 
medical data from 1240 representative French GPs was used. Patients over 50 y of 
age were included over a period of one year where a diagnosis of osteoarthritis associ-
ated with the initiation of an SYSADOA prescription was identiﬁ ed in the DA database 
(patient had been monitored for at least 6 months). RESULTS: In total, 3141 patients 
were included in the study. The patient proﬁ le is similar regardless of the treatment 
group considered (68% female, average age of 66, 50% patients the diagnosis dates 
from less than 1 year). The use of NSAIDs at the outset does not signiﬁ cantly differ 
among the groups of patients (25%). About 30% of patients discontinue their NSAID 
therapy upon initiation of treatment with SYSADOA. This proportion did not vary 
signiﬁ cantly with the SYSADOA considered. More than 40% of patients discontinued 
treatment with NSAIDs during the 6-month follow-up period. 20% of patients who 
continued treatment with NSAIDs increased the dosage or duration of the NSAID 
therapy. About 45% of patients beneﬁ ted from a co-prescription of analgesics during 
the initiation of treatment with SYSADOA. This rate did not signiﬁ cantly vary among 
groups of patients. 21% of patients discontinued their treatment with analgesics after 
initiation of treatment with SSAAO. This proportion did not vary signiﬁ cantly with 
the SYSADOA considered. CONCLUSIONS: It is generally accepted that an economy 
of 20% of NSAIDs has a major impact on public health. Regardless of the prescribed 
SYSADOA, NSAID interruptions at initiation are approximately 30%, and nearly two 
thirds of patients with co-prescriptions of NSAIDs at the start of treatment stop or 
reduce this treatment within 6 months. The cost of complications related to anti-
inﬂ ammatory drugs would be around 150 million Euros. 
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OBJECTIVES: To compare the efﬁ cacy in terms of HAQ score between abatacept and 
other biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in patients with 
rheumatoid arthritis taking concomitant methotrexate (MTX) who have inadequate 
response to MTX (MTX-IR). METHODS: A systematic literature review identiﬁ ed 
controlled trials investigating the efﬁ cacy of abatacept (3 studies), etanercept (2), 
inﬂ iximab (3), adalimumab (2), certolizumab pegol (2) ritixumab (2), and tocilizumab 
(1) in MTX-IR patients. The identiﬁ ed trials were comparable in design, included 
patients, and concomitant treatment (MTX). Mixed treatment comparison analyses 
were performed on HAQ change from baseline (CFB) at 24 and 52 weeks. Results 
were expressed as difference in HAQ CFB score between treatments and expected 
HAQ CFB and the 95% Credible Interval (CrI) per treatment at 24 and 52 weeks. 
RESULTS: The analysis of HAQ CFB at 24 weeks showed that abatacept/MTX is 
more efﬁ cacious than MTX monotherapy (−0.30, 95%CrI: −0.40; −0.19) and shows 
small numeric differences versus other biologics/MTX (range: −0.11:0.08). The 
expected mean HAQ CFB at 24 weeks for abatacept (−0.58) was superior to placebo 
(−0.28) and comparable to all the alternative treatments (adjusted mean between −0.47 
and −0.66). The ﬁ ndings at 52 weeks are in line with those at 24-weeks, although no 
data was available for tocilizumab and golimumab. Scenario analyses conﬁ rmed the 
robustness of the ﬁ ndings. CONCLUSIONS: All biologic DMARDs in combination 
with MTX in the treatment of MTX-IR patients resulted in improvements from 
baseline in HAQ score compared to MTX monotherapy at 24 and 52 weeks. All 
biologic DMARDs in combination with MTX are expected to result in a comparable 
improvement in HAQ score.
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OBJECTIVES: Interfaces are interactive dashboards built with programs like Visual 
Basic for Applications, Crystal Xcelsius or Java. We aimed to demonstrate how IEI 
allow the translation of pharmacoeconomic studies’ results into understandable pro-
jections to decision makers. We present the economic evaluation of rivaroxaban in 
the prevention of thromboembolic events as a case study. METHODS: A model evalu-
ating rivaroxaban in patients undergoing total knee and hip replacement was used. 
The model was adapted to different decision makers needs, namely Health Mainte-
nance Organizations (HMO), hospitals, and physicians focused only on clinical out-
comes. For each perspective, the following parameters could be customized: state 
taxes, time horizon of the analysis, choice of comparator (enoxaparin, dabigatran or 
both), duration of hospitalization, unit costs (drugs, treatment and diagnosis 
resources), eligible population and market share of comparators over the following 
ﬁ ve years. RESULTS: The IEI design for this case demonstrated that, under the per-
spective of an HMO with 200.000 lives, considering a base case where 80% of patients 
are treated with enoxaparin and 20% with dabigatran, and replacing every year 10% 
of enoxaparin cases with rivaroxaban would result in a budget impact of (-R$46,155) 
in 4 years for knee and hip replacement cases. The potential impact for cost offsets 
for the whole private system would be of (-R$8.3 million). Under the perspective of 
